The Latest released survey report on Global Ophthalmology Drugs and Devices Market aims to deliver an in-depth outline regarding the trends and market development scenario to outpace market with relevant strategies. This also report provide the details about industry overview and analysis about size, share, growth,.
Retinal Disorder Treatment Market Research Report by Type, by Dosage Form, by Distribution Channel - United States Forecast to 2025 - Cumulative Impact of COVID-19
Retinal Disorder Treatment Market Research Report by Type (Diabetic Retinopathy and Macular Degeneration), by Dosage Form (Capsules & Tablets, Eye Drops, Eye Solutions, Gels, and Ointments), by Distribution Channel - United States Forecast to 2025 - Cumulative Impact of COVID-19
May 10, 2021 08:59 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 10, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Retinal Disorder Treatment Market Research Report by Type, by Dosage Form, by Distribution Channel - United States Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p06063323/?utm source=GNW
Local hero honoured for efforts to save injured teen - Medicine Hat NewsMedicine Hat News medicinehatnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicinehatnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global ophthalmic drugs market size is expected to reach USD 60.3 billion by 2028. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028.
An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.
Moreover, due to COVID-19, it has become increasingly unsafe for individuals to touch their face several times a day, which is a known cause of transmission. Therefore, companies are developing long-acting, hands-free therapies to combat such challenges.
expected to reach USD 60.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected
to expand at a CAGR of 6.4% from 2021 to 2028. An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.
Key suggestions from the report:
In 2020, anti-VEGF agents dominated the market owing to high preference by ophthalmologists, enhanced tissue penetration, and rapid responsive rates